Recursion CSO heads west for mini-brain upstart; Novartis vet steps up to the plate as CFO for Andrew Hirsch at C4 Therapeutics
A few months ago, as Recursion hammered out an IPO that would value them at over $3 billion, its CSO, Sharath Hegde, hopped on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
